Xeris Biopharma (NASDAQ:XERS) Insider Sells $147,900.00 in Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Steven Pieper sold 17,400 shares of the business’s stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $8.50, for a total value of $147,900.00. Following the completion of the transaction, the insider directly owned 1,393,653 shares in the company, valued at $11,846,050.50. The trade was a 1.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Steven Pieper also recently made the following trade(s):

• On Tuesday, July 7th, Steven Pieper sold 27,600 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.52, for a total value of $235,152.00.

Xeris Biopharma Trading Down 0.6%

Shares of XERS opened at $8.62 on Friday. The stock has a fifty day moving average price of $6.81 and a two-hundred day moving average price of $6.67. The company has a debt-to-equity ratio of 17.00, a quick ratio of 1.50 and a current ratio of 2.12. Xeris Biopharma Holdings, Inc. has a 52-week low of $4.87 and a 52-week high of $10.08. The company has a market cap of $1.49 billion, a price-to-earnings ratio of 143.67 and a beta of 0.62.

Xeris Biopharma (NASDAQ:XERS) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.01 EPS for the quarter. The company had revenue of $83.13 million for the quarter, compared to analyst estimates of $79.83 million. Xeris Biopharma had a return on equity of 735.00% and a net margin of 3.81%. Analysts predict that Xeris Biopharma Holdings, Inc. will post 0.12 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, May 11th. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $10.80.

Institutional Investors Weigh In On Xeris Biopharma

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Kestra Advisory Services LLC bought a new stake in shares of Xeris Biopharma during the fourth quarter worth $25,000. KBC Group NV bought a new position in Xeris Biopharma in the first quarter valued at about $27,000. Caitong International Asset Management Co. Ltd boosted its holdings in Xeris Biopharma by 9,276.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company’s stock valued at $59,000 after acquiring an additional 7,421 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Xeris Biopharma by 29.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company’s stock valued at $63,000 after acquiring an additional 1,820 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. increased its position in Xeris Biopharma by 179.3% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 7,789 shares of the company’s stock worth $63,000 after purchasing an additional 5,000 shares during the period. 42.75% of the stock is owned by institutional investors and hedge funds.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.